Bahl & Gaynor’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $582K | Sell |
20,743
-4,700
| -18% | -$125K | ﹤0.01% | 268 |
|
|
2025
Q4 | $634K | Sell |
25,443
-3,962
| -13% | -$99.9K | ﹤0.01% | 262 |
|
|
2025
Q3 | $749K | Sell |
29,405
-2,699
| -8% | -$66.6K | ﹤0.01% | 252 |
|
|
2025
Q2 | $778K | Sell |
32,104
-10,066
| -24% | -$235K | ﹤0.01% | 255 |
|
|
2025
Q1 | $1.07M | Sell |
42,170
-5,812
| -12% | -$152K | 0.01% | 238 |
|
|
2024
Q4 | $1.27M | Sell |
47,982
-18,522
| -28% | -$502K | 0.01% | 233 |
|
|
2024
Q3 | $1.92M | Sell |
66,504
-3,357
| -5% | -$97.9K | 0.01% | 213 |
|
|
2024
Q2 | $1.95M | Sell |
69,861
-5,084
| -7% | -$140K | 0.01% | 207 |
|
|
2024
Q1 | $2.08M | Sell |
74,945
-7,046
| -9% | -$196K | 0.01% | 207 |
|
|
2023
Q4 | $2.36M | Sell |
81,991
-18,225
| -18% | -$551K | 0.01% | 195 |
|
|
2023
Q3 | $3.32M | Sell |
100,216
-12,200
| -11% | -$431K | 0.02% | 176 |
|
|
2023
Q2 | $4.12M | Buy |
112,416
+305
| +0.3% | +$11.9K | 0.03% | 170 |
|
|
2023
Q1 | $4.57M | Sell |
112,111
-8,835
| -7% | -$382K | 0.02% | 164 |
|
|
2022
Q4 | $6.2M | Sell |
120,946
-4,377
| -3% | -$210K | 0.04% | 142 |
|
|
2022
Q3 | $5.48M | Buy |
125,323
+1,963
| +2% | +$95.4K | 0.04% | 148 |
|
|
2022
Q2 | $6.47M | Buy |
123,360
+486
| +0.4% | +$24.8K | 0.04% | 153 |
|
|
2022
Q1 | $6.36M | Sell |
122,874
-406
| -0.3% | -$21.1K | 0.05% | 142 |
|
|
2021
Q4 | $7.28M | Sell |
123,280
-518
| -0.4% | -$25.7K | 0.04% | 144 |
|
|
2021
Q3 | $5.33M | Sell |
123,798
-6,755
| -5% | -$299K | 0.03% | 160 |
|
|
2021
Q2 | $5.11M | Sell |
130,553
-3,862
| -3% | -$150K | 0.03% | 163 |
|
|
2021
Q1 | $4.87M | Sell |
134,415
-554,640
| -80% | -$19.7M | 0.03% | 168 |
|
|
2020
Q4 | $25.4M | Sell |
689,055
-69,594
| -9% | -$2.55M | 0.16% | 74 |
|
|
2020
Q3 | $26.4M | Sell |
758,649
-13,319
| -2% | -$467K | 0.19% | 70 |
|
|
2020
Q2 | $23.9M | Sell |
771,968
-2,351,795
| -75% | -$79.9M | 0.18% | 71 |
|
|
2020
Q1 | $96.7M | Sell |
3,123,763
-595,617
| -16% | -$20.3M | 0.84% | 39 |
|
|
2019
Q4 | $138M | Sell |
3,719,380
-1,265,291
| -25% | -$45.1M | 0.96% | 37 |
|
|
2019
Q3 | $170M | Buy |
4,984,671
+400,419
| +9% | +$14.6M | 1.23% | 31 |
|
|
2019
Q2 | $188M | Buy |
4,584,252
+1,147,991
| +33% | +$45.6M | 1.4% | 25 |
|
|
2019
Q1 | $138M | Buy |
3,436,261
+128,108
| +4% | +$5.13M | 1.27% | 32 |
|
|
2018
Q4 | $137M | Buy |
3,308,153
+1,190,472
| +56% | +$49.4M | 1.47% | 27 |
|
|
2018
Q3 | $88.5M | Sell |
2,117,681
-1,100,857
| -34% | -$42.4M | 1.14% | 31 |
|
|
2018
Q2 | $111M | Buy |
3,218,538
+241,194
| +8% | +$8.24M | 1.16% | 30 |
|
|
2018
Q1 | $100M | Sell |
2,977,344
-292,510
| -9% | -$10.1M | 1.1% | 29 |
|
|
2017
Q4 | $112M | Sell |
3,269,854
-47,047
| -1% | -$1.6M | 1.16% | 27 |
|
|
2017
Q3 | $112M | Sell |
3,316,901
-395,457
| -11% | -$12.7M | 1.23% | 30 |
|
|
2017
Q2 | $118M | Sell |
3,712,358
-330,087
| -8% | -$10.4M | 1.35% | 28 |
|
|
2017
Q1 | $131M | Buy |
4,042,445
+172,417
| +4% | +$5.44M | 1.51% | 21 |
|
|
2016
Q4 | $119M | Sell |
3,870,028
-382,216
| -9% | -$11.7M | 1.46% | 25 |
|
|
2016
Q3 | $137M | Buy |
4,252,244
+401,642
| +10% | +$13.4M | 1.65% | 21 |
|
|
2016
Q2 | $129M | Sell |
3,850,602
-166,640
| -4% | -$5.32M | 1.67% | 20 |
|
|
2016
Q1 | $113M | Buy |
4,017,242
+66,518
| +2% | +$1.9M | 1.5% | 23 |
|
|
2015
Q4 | $121M | Sell |
3,950,724
-640,579
| -14% | -$20.2M | 1.66% | 18 |
|
|
2015
Q3 | $137M | Buy |
4,591,303
+15,674
| +0.3% | +$503K | 1.97% | 11 |
|
|
2015
Q2 | $146M | Buy |
4,575,629
+218,509
| +5% | +$7.12M | 1.96% | 13 |
|
|
2015
Q1 | $144M | Buy |
4,357,120
+4,253,519
| +4,106% | +$135M | 1.95% | 14 |
|
|
2014
Q4 | $3.06M | Buy |
103,601
+9,359
| +10% | +$268K | 0.04% | 146 |
|
|
2014
Q3 | $2.64M | Buy |
94,242
+3,031
| +3% | +$85.1K | 0.04% | 154 |
|
|
2014
Q2 | $2.57M | Sell |
91,211
-2,211
| -2% | -$63K | 0.04% | 158 |
|
|
2014
Q1 | $2.85M | Buy |
93,422
+492
| +0.5% | +$14.7K | 0.05% | 146 |
|
|
2013
Q4 | $2.7M | Buy |
92,930
+62
| +0.1% | +$1.8K | 0.04% | 147 |
|
|
2013
Q3 | $2.53M | Sell |
92,868
-5,525
| -6% | -$150K | 0.05% | 141 |
|
|
2013
Q2 | $2.62M | Buy |
+98,393
| New | +$2.72M | 0.05% | 139 |
|
Other funds holding PFE
VCM
VPM
Bahl & Gaynor's PFE Position: Q1 2026 in Review
Bahl & Gaynor reduced its Pfizer (PFE) stake by 18% in Q1 2026, selling an estimated $125K and leaving 20,743 shares worth $582K. The position accounts for ﹤0.01% of the portfolio, ranked #268.
Bahl & Gaynor first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $188M in Q2 2019. 2,946 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Bahl & Gaynor held 20,743 shares of Pfizer worth $582K as of Q1 2026.
- Bahl & Gaynor sold 4,700 Pfizer shares in Q1 2026, an estimated $125K.
- Pfizer made up ﹤0.01% of Bahl & Gaynor's portfolio in Q1 2026, its #268 holding.
- Bahl & Gaynor first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Bahl & Gaynor's Pfizer position peaked at $188M in Q2 2019.
- 2,946 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Bahl & Gaynor's 13F filing for Q1 2026, filed 7 May 2026.